Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - other diseases
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Release according to Article 26, Section 1 of the WpHG ...

28.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Voluntary recall of human albumin

26.04.2017, News

Biotest: Voluntary recall of human albumin - Already quarantined batches of human albumin are recalled - Consequences of the one-time effect on Sales and EBIT are currently being evaluated - As ... [More]

Biotest recalls human albumin and reduces forecast

26.04.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest recalls human albumin and reduces forecast Dreieich, 26 April 2017. In close co-operation with regulatory ... [More]

Biotest AG opens sixth plasma collection centre in Hung...

19.04.2017, News

Biotest AG opens sixth plasma collection centre in Hungary - 14 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 19 April 2017. Biotest ... [More]

Biotest informs about limited availability of albumin

13.04.2017, News

Biotest informs about limited availability of albumin - Due to an equipment failure the availability of albumin is currently limited - Consequences on sales and annual results are currently not ... [More]

Release according to Article 26, Section 1 of the WpHG ...

13.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

11.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Correction of a release from 06.04.2017, 14:54 CET/CEST...

11.04.2017, PVR

Announcement JO HAMBRO Capital Management Limited informed us that they retract their notification published by us on 6h April 2017, as no thresholds had been crossed which are relevant for ... [More]

Release according to Article 26, Section 1 of the WpHG ...

07.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Biotest AG and Creat enter into Business Combination Ag...

07.04.2017, News

Biotest AG and Creat enter into Business Combination Agreement - Chinese strategic investor Creat to make a voluntary public takeover offer - Shareholders will be offered EUR 28.50 in cash per ... [More]

Takeover Offer: Chinese strategic investor Creat to mak...

07.04.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG ... [More]

Release according to Article 26, Section 1 of the WpHG ...

06.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Discussions regarding business combination

29.03.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Discussions regarding business combination Dreieich, 29 March 2017. Biotest Aktiengesellschaft and Creat Group ... [More]

Discussions regarding possible business combination

29.03.2017, News

Discussions regarding possible business combination Dreieich, 29 March 2017. Biotest AG announced today that it is in discussion with Creat Group Corporation (Creat), a leading Chinese investment ... [More]

ImmunoGen has elected not to exercise its late stage co...

24.03.2017, News

ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - License agreement with ImmunoGen will continue ... [More]

Recombinant clotting factor VIII with the name Vihuma(R...

01.03.2017, News

Recombinant clotting factor VIII with the name Vihuma(R) approved - Market launch in Germany end of April 2017 - Vihuma(R) is a 4th generation recombinant human factor VIII preparation ... [More]

Proceedings against Biotest AG have been closed

17.02.2017, News

Proceedings against Biotest AG have been closed Dreieich, 17 February 2017. Biotest AG has agreed with the Frankfurt public prosecution on a mutual termination of the proceedings against the ... [More]

EUR 64.4 million operating profit in core business of B...

16.02.2017, News

EUR 64.4 million operating profit in core business of Biotest Dreieich, 16 February 2017. In line with the strategic realignment Biotest has restructured its US Therapy business. In the next ... [More]

Release according to Article 26, Section 1 of the WpHG ...

27.01.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

First patient treated in the next clinical phase III st...

25.01.2017, News

First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP) - Study no. 992 is the second pivotal phase III study ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Letter to shareholders

preview

Letter to shareholders - 4.11.2015
PDF, 162 KB
[ Download ]